Pipeline delivers ‘exciting’ new treatments in autoimmune biliary disease

The pipeline for cholestatic diseases is really exciting.

You know, we were excited to just get one new thing, and now we have two approved PPARs for PBC, a whole onslaught of things for PSC that we hope might translate to, developments that are clinically important.

We have another PPAR that is in evaluation for, PBC or autoimmune-related cholangiopathy.

And so I think that we're realizing that the treatment landscape for disease-modifying options is definitely going to grow.

I think that there's also a ton of, work on the extrahepatic manifestations of, autoimmune-related cholangiopathy.